Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation

NCT01517347 · clinicaltrials.gov ↗
NA
Phase
TERMINATED
Status
90
Enrollment
OTHER
Sponsor class

Stopped Because the conditional power was 0.083, the Data and Safety Monitoring Board recommended halting the study due to futility after the 1st interim analysis.

Conditions

Interventions

Sponsor

Peking University People's Hospital